XSWX
GALD
Market cap52bUSD
, Last price
CHF
Name
Galderma Group AG
Chart & performance
P/E
—
P/S
—
EPS
2.70
Vol. 1Y
—
Shs. 5Y
—
Rev. 5Y
%
Div Yld LY
—
Div Yld TTM
—
Revenues
5.24b
+7.20%
Net income
642m
+152.47%
CFO
1.19b
+175.73%
Dividend
Apr 24, 20260.35 CHF/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 1981 and is headquartered in Zug, Switzerland.
Related entities
Subsidiaries (2)
Galderma Finance Europe B.V.
Galderma SA
Key people
Thomas Ebeling
Non-Executive Independent Chairman of the Board · since 2022
Chief Executive Officer, Executive Director, Head of the Executive Committee · since 2022
Non-Executive Independent Vice Chairman of the Board · since 2022
Chief Financial Officer, Member of the Executive Committee · since 2022
Adrian Murphy
Head of Global Operations, Member of the Executive Committee · since 2024
Michael Bauer
Non-Executive Director · since 2022
Marcus Brennecke
Non-Executive Director · since 2024
Daniel Browne
Non-Executive Independent Director · since 2022
Non-Executive Independent Director · since 2022
Non-Executive Independent Director · since 2022
Non-Executive Independent Director · since 2025
Headquarters & legal address
Zählerweg 10
Zug 6300
CH
Zug 6300
CH
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | |
| Income | |||||
Revenues | |||||
Cost of revenue | |||||
Unusual Expense (Income) | |||||
NOPBT | |||||
NOPBT Margin | |||||
Operating Taxes | |||||
Tax Rate | |||||
NOPAT | |||||
Net income | |||||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | |||||
BB yield | |||||
| Debt | |||||
Debt current | |||||
Long-term debt | |||||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | |||||
| Cash flow | |||||
Cash from operating activities | |||||
CAPEX | |||||
Cash from investing activities | |||||
Cash from financing activities | |||||
FCF | |||||
| Balance | |||||
Cash | |||||
Long term investments | |||||
Excess cash | |||||
Stockholders' equity | |||||
Invested Capital | |||||
ROIC | |||||
ROCE | |||||
| EV | |||||
Common stock shares outstanding | |||||
Price | |||||
Market cap | |||||
EV | |||||
EBITDA | |||||
EV/EBITDA | |||||
Interest | |||||
Interest/NOPBT | |||||